The pathophysiology of heart failure.

Heart failure is a clinical syndrome that results when the heart is unable to provide sufficient blood flow to meet metabolic requirements or accommodate systemic venous return. This common condition affects over 5 million people in the United States at a cost of $10-38 billion per year. Heart failure results from injury to the myocardium from a variety of causes including ischemic heart disease, hypertension, and diabetes. Less common etiologies include cardiomyopathies, valvular disease, myocarditis, infections, systemic toxins, and cardiotoxic drugs. As the heart fails, patients develop symptoms which include dyspnea from pulmonary congestion, and peripheral edema and ascites from impaired venous return. Constitutional symptoms such as nausea, lack of appetite, and fatigue are also common. There are several compensatory mechanisms that occur as the failing heart attempts to maintain adequate function. These include increasing cardiac output via the Frank-Starling mechanism, increasing ventricular volume and wall thickness through ventricular remodeling, and maintaining tissue perfusion with augmented mean arterial pressure through activation of neurohormonal systems. Although initially beneficial in the early stages of heart failure, all of these compensatory mechanisms eventually lead to a vicious cycle of worsening heart failure. Treatment strategies have been developed based upon the understanding of these compensatory mechanisms. Medical therapy includes diuresis, suppression of the overactive neurohormonal systems, and augmentation of contractility. Surgical options include ventricular resynchronization therapy, surgical ventricular remodeling, ventricular assist device implantation, and heart transplantation. Despite significant understanding of the underlying pathophysiological mechanisms in heart failure, this disease causes significant morbidity and carries a 50% 5-year mortality.

[1]  N Westerhof,et al.  Haemodynamic basis for the development of left ventricular failure in systolic hypertension and for its logical therapy. , 1995, Journal of hypertension.

[2]  S. Shaw,et al.  Neuroendocrine effects on the heart and targets for therapeutic manipulation in heart failure. , 2009, Cardiovascular therapeutics.

[3]  Carlos Orrego,et al.  Cytokines and acute heart failure , 2008, Critical care medicine.

[4]  J. Murabito,et al.  Lifetime Risk for Developing Congestive Heart Failure: The Framingham Heart Study , 2002, Circulation.

[5]  N. Tkacs,et al.  Current Concepts of Neurohormonal Activation in Heart Failure: Mediators and Mechanisms , 2008, AACN advanced critical care.

[6]  Marcia A. Gangemi PATHOPHYSIOLOGY OF HEART DISEASE: A COLLABORATIVE PROJECT OF MEDICAL STUDENTS AND FACULTY. , 1995 .

[7]  D. Mozaffarian,et al.  Heart disease and stroke statistics--2011 update: a report from the American Heart Association. , 2011, Circulation.

[8]  J. Mcanulty,et al.  CARDIOVASCULAR PHYSIOLOGY , 1981, Clinical obstetrics and gynecology.

[9]  M. A. English,et al.  Congestive heart failure: public and private burden. , 1995, Critical care nursing quarterly.

[10]  E. Antman,et al.  ACC/AHA PRACTICE GUIDELINES ACC/AHA Guidelines for the Evaluation and Management of Chronic Heart Failure in the Adult: Executive Summary , 2002 .

[11]  M. Drazner,et al.  2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2013, Journal of the American College of Cardiology.

[12]  Michael Y. Henein Heart Failure in Clinical Practice , 2010 .

[13]  M. Dunlap,et al.  Renal hemodynamics in heart failure: implications for treatment , 2008, Current opinion in nephrology and hypertension.

[14]  Fach,et al.  Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in-Congestive Heart Failure (MERIT-HF) , 1999, The Lancet.

[15]  C. Boulanger,et al.  Secondary endothelial dysfunction: hypertension and heart failure. , 1999, Journal of molecular and cellular cardiology.

[16]  J. Januzzi,et al.  Natriuretic peptide testing in heart failure. , 2011, Circulation.

[17]  S. Silver,et al.  Heart Failure , 1937, The New England journal of medicine.

[18]  L. S. Lilly,et al.  Pathophysiology of Heart Disease: A Collaborative Project of Medical Students and Faculty , 2002 .

[19]  R. Kronmal,et al.  Differences in the incidence of congestive heart failure by ethnicity: the multi-ethnic study of atherosclerosis. , 2008, Archives of internal medicine.

[20]  Guadalajara Boo Jf,et al.  [What is heart failure?]. , 1998, Archivos del Instituto de Cardiologia de Mexico.

[21]  D. Kass,et al.  Mechanical dyssynchrony in dilated cardiomyopathy with intraventricular conduction delay as depicted by 3D tagged magnetic resonance imaging. , 2000, Circulation.

[22]  M. Dolgin,et al.  Nomenclature and Criteria for Diagnosis of Diseases of the Heart and Great Vessels , 1994 .